Objective: Isoforms of monoamine oxidase (MAO-A and-B) which are responsible for the degradation of neuromediators are involved in many diseases, and MAO inhibitors are used for the treatment of some diseases such as depression, Alzheimer's and Parkinson's diseases. Thus, a novel compound, SH2U was synthesized and its ability for the inhibition of human MAO (hMAO) activity was investigated by our group. In addition, the interaction of SH2U with hMAO isoforms have been investigated in detail using molecular modelling technics. It has been found that SH2U inhibited hMAO-B potently, selectively, competitively and reversibly suggesting that the novel compound may be a promising drug agent for the treatment of Parkinson's and Alzheimer's diseases. Methods: 1-(3,5-dichloro-2-hydroxyphenyl)-3p-tolylprop-2-ene-1-on (3',5'-Dichloro-2'-hydroxy-4-methyl chalcone) was prepared via the reaction
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.